Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Palivizumab‐Resistant Human Respiratory Syncytial Virus Infection in Infancy

8 Jun 2010

Abstract excerpt

Palivizumab-resistant respiratory syncytial virus was isolated from an infant treated with palivizumab. A stable mutation at codon 276 led to a nearly complete resistance to palivizumab. Additional studies revealed a second mutation at codon 272. Further passage of the virus led to a complete loss of binding of palivizumab.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Congenital Diaphragmatic Hernia Studies
Share to Respiratory viral infections research
Share to Viral gastroenteritis research and epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 20528472
DOI: 10.1086/653534

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Palivizumab‐Resistant Human Respiratory Syncytial Virus Infection in InfancyPMID 20528472Read ↗

Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab.Semantic proximity Read ↗

Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants.Semantic proximity Read ↗

Molecular characterization of respiratory syncytial viruses infecting children reported to have received palivizumab immunoprophylaxis.Semantic proximity Read ↗

Variable resistance to palivizumab in cotton rats by respiratory syncytial virus mutants.Semantic proximity Read ↗

Respiratory syncytial virus escape mutant derived in vitro resists palivizumab prophylaxis in cotton rats.Semantic proximity Read ↗

Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.Semantic proximity Read ↗

Use of palivizumab and infection control measures to control an outbreak of respiratory syncytial virus in a neonatal intensive care unit confirmed by real-time polymerase chain reaction.Semantic proximity Read ↗

An investigation of the genetic basis of increased susceptibility to neutralization by anti-fusion glycoprotein antibody arising on passage of human respiratory syncytial virus in cell culture.Semantic proximity Read ↗

Neutralizing epitopes of RSV and palivizumab resistance in Japan.Semantic proximity Read ↗

Escape from neutralization by the respiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein.Semantic proximity Read ↗

In Vivo Selection of Respiratory Syncytial Viruses Resistant to PalivizumabSemantic proximity Read ↗

Cell fusion assay by expression of respiratory syncytial virus (RSV) fusion protein to analyze the mutation of palivizumab-resistant strains.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.